China Health Care Reform Plan To Favor Government-Made Drugs
This article was originally published in PharmAsia News
China's new three-year health care reform guidelines include a system designed to force down the cost of prescription drugs deemed essential. The government itself is to produce and distribute essential medicines under its own control and supervision. It plans to issue a list of such drugs later this year. The number of drugs to be placed on the list has not been disclosed, but the Ministry of Health had said earlier it would be based on the 400 drugs the World Health Organization recommends be accessible. Those considered essential are based on the prevalence of a disease and the comparative cost-effectiveness of the drugs. (Click here for more)
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.